⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Symbios Orthopédie SA and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Symbios Orthopédie SA
↗Yverdon-les-Bains, Switzerland
Symbios is a Swiss medical technology company and a leader in individualized (custom-made) orthopedic implants for hip and knee joint replacement. Founded in 1989, the company focuses on designing and manufacturing implants that adapt to each patient's unique anatomy, aiming to restore mobility and improve clinical outcomes while reducing hospital stock requirements.
The company utilizes a digital-centric industrial model and has pioneered custom implant manufacturing for over 30 years. Symbios maintains a strong market position in EMEA and has been expanding its international footprint into Australia and the United States, supported by recent debt financing to fuel its growth strategy.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$20M-$30M
Founded:1989
Ownership:private
Status:operating
FUNDING
Investors:Kartesia (Debt financing)
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A
Modalities:Custom-made orthopedic implants
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Symbios Deutschland GmbH, Symbios Orthopaedics PTY LTD (Australia), Symbios Belgium & Luxembourg
Key Partnerships:Kartesia (Financing partner)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Jean Plé - President and CEO
Nicolas Guignet - VP Regulatory Affairs & QA
Bart Lagae - VP of Marketing
Scientific Founders:Jean Plé, Jacques Essinger, Jean-Manuel Aubaniac
LINKS
Website:symbios.ch
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Symbios Orthopédie SA. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.